Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(3):316–322. doi: 10.1038/bjc.1996.55

Effect of transient expression of the oestrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells.

W L Wang 1, J S Thomsen 1, W Porter 1, M Moore 1, S Safe 1
PMCID: PMC2074440  PMID: 8562336

Abstract

Hs578T human breast cancer cells are an oestrogen receptor (ER)-negative cell line. Treatment of these cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) resulted in formation of a 6.9 S nuclear aryl hydrocarbon (Ah) receptor complex, which bound to a [32P]dioxin-responsive element in a gel electrophoretic mobility shift assay. However, TCDD does not induce CYP1A1 gene expression or chloramphenicol acetyl transferase (CAT) activity in cells transiently transfected with pRNH11c or pMCAT5.12, which are Ah-responsive plasmids derived from the 5'-flanking region of the human and murine CYP1A1 genes respectively. Restoration of Ah responsiveness was investigated by co-transfecting Hs578T cells with pRNH11c or pMCAT5.12 and plasmids that express the ER (hER), Ah receptor (AhR) and AhR nuclear translocator (Arnt) proteins. ER expression resulted in significantly increased basal CAT activity; however, TCDD did not induce CAT activity in the transiently transfected cells. Expression of the AhR or Arnt proteins did not alter basal or inducible CAT activity. Expression of N- or C-terminal truncated ER in Hs578T resulted in differential regulation of Ah responsiveness. In Hs578T cells transiently expressing the ER, which contains C-terminal deletions (amino acids 282-595), basal CAT activity was also increased; however, Ah responsiveness was not restored. In contrast, transient expression of N-terminal-deleted (amino acids 1-178) ER resulted in a marked decrease in basal CAT activity but a restoration of Ah responsiveness. These results suggest that basal and inducible CAT activity in Hs578T cells transiently transfected with pRNH11c is modulated differentially by ER domains that are present in the N- and C-terminal regions of the ER.

Full text

PDF
316

Images in this article

318Figure 2
on p.318
319Figure 3
on p.319
320Figure 4
on p.320

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anttila S., Hietanen E., Vainio H., Camus A. M., Gelboin H. V., Park S. S., Heikkilä L., Karjalainen A., Bartsch H. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int J Cancer. 1991 Mar 12;47(5):681–685. doi: 10.1002/ijc.2910470509. [DOI] [PubMed] [Google Scholar]
  2. Arellano L. O., Wang X., Safe S. Effects of cycloheximide on the induction of CYP1A1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in three human breast cancer cell lines. Carcinogenesis. 1993 Feb;14(2):219–222. doi: 10.1093/carcin/14.2.219. [DOI] [PubMed] [Google Scholar]
  3. Boucher P. D., Ruch R. J., Hines R. N. Specific nuclear protein binding to a negative regulatory element on the human CYP1A1 gene. J Biol Chem. 1993 Aug 15;268(23):17384–17391. [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  5. Burbach K. M., Poland A., Bradfield C. A. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8185–8189. doi: 10.1073/pnas.89.17.8185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chaloupka K., Steinberg M., Santostefano M., Rodriguez L. V., Goldstein L., Safe S. Induction of Cyp1a-1 and Cyp1a-2 gene expression by a reconstituted mixture of polynuclear aromatic hydrocarbons in B6C3F1 mice. Chem Biol Interact. 1995 Jun 14;96(3):207–221. doi: 10.1016/0009-2797(94)03586-w. [DOI] [PubMed] [Google Scholar]
  7. Daffada A. A., Johnston S. R., Smith I. E., Detre S., King N., Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res. 1995 Jan 15;55(2):288–293. [PubMed] [Google Scholar]
  8. Denison M. S., Deal R. M. The binding of transformed aromatic hydrocarbon (Ah) receptor to its DNA recognition site is not affected by metal depletion. Mol Cell Endocrinol. 1990 Feb 12;69(1):51–57. doi: 10.1016/0303-7207(90)90088-p. [DOI] [PubMed] [Google Scholar]
  9. Ema M., Sogawa K., Watanabe N., Chujoh Y., Matsushita N., Gotoh O., Funae Y., Fujii-Kuriyama Y. cDNA cloning and structure of mouse putative Ah receptor. Biochem Biophys Res Commun. 1992 Apr 15;184(1):246–253. doi: 10.1016/0006-291x(92)91185-s. [DOI] [PubMed] [Google Scholar]
  10. Foldes R. L., Bresnick E. Inducibility of rat liver cytochrome P-450IA1 (P-450c) mRNA during the partial inhibition of protein synthesis. Biochem Pharmacol. 1989 Mar 15;38(6):1017–1019. doi: 10.1016/0006-2952(89)90295-5. [DOI] [PubMed] [Google Scholar]
  11. Fujisawa-Sehara A., Sogawa K., Yamane M., Fujii-Kuriyama Y. Characterization of xenobiotic responsive elements upstream from the drug-metabolizing cytochrome P-450c gene: a similarity to glucocorticoid regulatory elements. Nucleic Acids Res. 1987 May 26;15(10):4179–4191. doi: 10.1093/nar/15.10.4179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fuqua S. A., Allred D. C., Auchus R. J. Expression of estrogen receptor variants. J Cell Biochem Suppl. 1993;17G:194–197. doi: 10.1002/jcb.240531135. [DOI] [PubMed] [Google Scholar]
  13. Gonzalez F. J., Nebert D. W. Autoregulation plus upstream positive and negative control regions associated with transcriptional activation of the mouse P1(450) gene. Nucleic Acids Res. 1985 Oct 25;13(20):7269–7288. doi: 10.1093/nar/13.20.7269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gradin K., Wilhelmsson A., Poellinger L., Berghard A. Nonresponsiveness of normal human fibroblasts to dioxin correlates with the presence of a constitutive xenobiotic response element-binding factor. J Biol Chem. 1993 Feb 25;268(6):4061–4068. [PubMed] [Google Scholar]
  15. Harris M., Piskorska-Pliszczynska J., Zacharewski T., Romkes M., Safe S. Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor. Cancer Res. 1989 Aug 15;49(16):4531–4535. [PubMed] [Google Scholar]
  16. Hines R. N., Mathis J. M., Jacob C. S. Identification of multiple regulatory elements on the human cytochrome P450IA1 gene. Carcinogenesis. 1988 Sep;9(9):1599–1605. doi: 10.1093/carcin/9.9.1599. [DOI] [PubMed] [Google Scholar]
  17. Hoffman E. C., Reyes H., Chu F. F., Sander F., Conley L. H., Brooks B. A., Hankinson O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science. 1991 May 17;252(5008):954–958. doi: 10.1126/science.1852076. [DOI] [PubMed] [Google Scholar]
  18. Ivy S. P., Tulpule A., Fairchild C. R., Averbuch S. D., Myers C. E., Nebert D. W., Baird W. M., Cowan K. H. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem. 1988 Dec 15;263(35):19119–19125. [PubMed] [Google Scholar]
  19. Jaiswal A. K., Gonzalez F. J., Nebert D. W. Human dioxin-inducible cytochrome P1-450: complementary DNA and amino acid sequence. Science. 1985 Apr 5;228(4695):80–83. doi: 10.1126/science.3838385. [DOI] [PubMed] [Google Scholar]
  20. Jones P. B., Durrin L. K., Galeazzi D. R., Whitlock J. P., Jr Control of cytochrome P1-450 gene expression: analysis of a dioxin-responsive enhancer system. Proc Natl Acad Sci U S A. 1986 May;83(9):2802–2806. doi: 10.1073/pnas.83.9.2802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jones P. B., Galeazzi D. R., Fisher J. M., Whitlock J. P., Jr Control of cytochrome P1-450 gene expression by dioxin. Science. 1985 Mar 22;227(4693):1499–1502. doi: 10.1126/science.3856321. [DOI] [PubMed] [Google Scholar]
  22. Kawai S., Nishizawa M. New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol. 1984 Jun;4(6):1172–1174. doi: 10.1128/mcb.4.6.1172-1174.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kawajiri K., Fujii-Kuriyama Y. P450 and human cancer. Jpn J Cancer Res. 1991 Dec;82(12):1325–1335. doi: 10.1111/j.1349-7006.1991.tb01800.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kellermann G., Shaw C. R., Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med. 1973 Nov 1;289(18):934–937. doi: 10.1056/NEJM197311012891802. [DOI] [PubMed] [Google Scholar]
  25. Kelsey K. T., Wiencke J. K., Spitz M. R. A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis. 1994 Jun;15(6):1121–1124. doi: 10.1093/carcin/15.6.1121. [DOI] [PubMed] [Google Scholar]
  26. Kumar V., Green S., Stack G., Berry M., Jin J. R., Chambon P. Functional domains of the human estrogen receptor. Cell. 1987 Dec 24;51(6):941–951. doi: 10.1016/0092-8674(87)90581-2. [DOI] [PubMed] [Google Scholar]
  27. Lusska A., Wu L., Whitlock J. P., Jr Superinduction of CYP1A1 transcription by cycloheximide. Role of the DNA binding site for the liganded Ah receptor. J Biol Chem. 1992 Jul 25;267(21):15146–15151. [PubMed] [Google Scholar]
  28. Moore M., Narasimhan T. R., Steinberg M. A., Wang X., Safe S. Potentiation of CYP1A1 gene expression in MCF-7 human breast cancer cells cotreated with 2,3,7,8-tetrachlorodibenzo-p-dioxin and 12-O-tetradecanoylphorbol-13-acetate. Arch Biochem Biophys. 1993 Sep;305(2):483–488. doi: 10.1006/abbi.1993.1451. [DOI] [PubMed] [Google Scholar]
  29. Morgan T. L., Maher V. M., McCormick J. J. Optimal parameters for the polybrene-induced DNA transfection of diploid human fibroblasts. In Vitro Cell Dev Biol. 1986 Jun;22(6):317–319. doi: 10.1007/BF02623404. [DOI] [PubMed] [Google Scholar]
  30. Murray G. I., Foster C. O., Barnes T. S., Weaver R. J., Ewen S. W., Melvin W. T., Burke M. D. Expression of cytochrome P450IA in breast cancer. Br J Cancer. 1991 Jun;63(6):1021–1023. doi: 10.1038/bjc.1991.222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nakachi K., Imai K., Hayashi S., Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993 Jul 1;53(13):2994–2999. [PubMed] [Google Scholar]
  32. Nelson D. R., Kamataki T., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993 Jan-Feb;12(1):1–51. doi: 10.1089/dna.1993.12.1. [DOI] [PubMed] [Google Scholar]
  33. Nemoto N., Sakurai J. Increase of CYP1A1 mRNA and AHH activity by inhibitors of either protein or RNA synthesis in mouse hepatocytes in primary culture. Carcinogenesis. 1991 Nov;12(11):2115–2121. doi: 10.1093/carcin/12.11.2115. [DOI] [PubMed] [Google Scholar]
  34. Pasanen M., Stacey S., Lykkesfeldt A., Briand P., Hines R., Autrup H. Induction of cytochrome P-450IA1 gene expression in human breast tumour cell lines. Chem Biol Interact. 1988;66(3-4):223–232. doi: 10.1016/0009-2797(88)90073-7. [DOI] [PubMed] [Google Scholar]
  35. Pyykkö K., Tuimala R., Aalto L., Perkiö T. Is aryl hydrocarbon hydroxylase activity a new prognostic indicator for breast cancer? Br J Cancer. 1991 Apr;63(4):596–600. doi: 10.1038/bjc.1991.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Reick M., Robertson R. W., Pasco D. S., Fagan J. B. Down-regulation of nuclear aryl hydrocarbon receptor DNA-binding and transactivation functions: requirement for a labile or inducible factor. Mol Cell Biol. 1994 Sep;14(9):5653–5660. doi: 10.1128/mcb.14.9.5653-5660.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Reyes H., Reisz-Porszasz S., Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 1992 May 22;256(5060):1193–1195. doi: 10.1126/science.256.5060.1193. [DOI] [PubMed] [Google Scholar]
  38. Robertson R. W., Zhang L., Pasco D. S., Fagan J. B. Aryl hydrocarbon-induced interactions at multiple DNA elements of diverse sequence--a multicomponent mechanism for activation of cytochrome P4501A1 (CYP1A1) gene transcription. Nucleic Acids Res. 1994 May 11;22(9):1741–1749. doi: 10.1093/nar/22.9.1741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Sivaraman L., Leatham M. P., Yee J., Wilkens L. R., Lau A. F., Le Marchand L. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res. 1994 Jul 15;54(14):3692–3695. [PubMed] [Google Scholar]
  40. Sterling K., Weaver J., Ho K. L., Xu L. C., Bresnick E. Rat CYP1A1 negative regulatory element: biological activity and interaction with a protein from liver and hepatoma cells. Mol Pharmacol. 1993 Sep;44(3):560–568. [PubMed] [Google Scholar]
  41. Swanson H. I., Bradfield C. A. The AH-receptor: genetics, structure and function. Pharmacogenetics. 1993 Oct;3(5):213–230. doi: 10.1097/00008571-199310000-00001. [DOI] [PubMed] [Google Scholar]
  42. Taioli E., Crofts F., Trachman J., Demopoulos R., Toniolo P., Garte S. J. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res. 1995 Feb 1;55(3):472–473. [PubMed] [Google Scholar]
  43. Thomsen J. S., Nissen L., Stacey S. N., Hines R. N., Autrup H. Differences in 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible CYP1A1 expression in human breast carcinoma cell lines involve altered trans-acting factors. Eur J Biochem. 1991 May 8;197(3):577–582. doi: 10.1111/j.1432-1033.1991.tb15946.x. [DOI] [PubMed] [Google Scholar]
  44. Thomsen J. S., Wang X., Hines R. N., Safe S. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis. 1994 May;15(5):933–937. doi: 10.1093/carcin/15.5.933. [DOI] [PubMed] [Google Scholar]
  45. Vickers P. J., Dufresne M. J., Cowan K. H. Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. Mol Endocrinol. 1989 Jan;3(1):157–164. doi: 10.1210/mend-3-1-157. [DOI] [PubMed] [Google Scholar]
  46. Villa E., Camellini L., Dugani A., Zucchi F., Grottola A., Merighi A., Buttafoco P., Losi L., Manenti F. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res. 1995 Feb 1;55(3):498–500. [PubMed] [Google Scholar]
  47. Wang X., Porter W., Krishnan V., Narasimhan T. R., Safe S. Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated decrease of the nuclear estrogen receptor in MCF-7 human breast cancer cells. Mol Cell Endocrinol. 1993 Oct;96(1-2):159–166. doi: 10.1016/0303-7207(93)90106-t. [DOI] [PubMed] [Google Scholar]
  48. Wang X., Rosengren R., Morrison V., Santostefano M., Safe S. Characterization of the aryl hydrocarbon receptor in the human C-4II cervical squamous carcinoma cell line. Biochem Pharmacol. 1992 Apr 1;43(7):1635–1642. doi: 10.1016/0006-2952(92)90223-6. [DOI] [PubMed] [Google Scholar]
  49. Watson A. J., Weir-Brown K. I., Bannister R. M., Chu F. F., Reisz-Porszasz S., Fujii-Kuriyama Y., Sogawa K., Hankinson O. Mechanism of action of a repressor of dioxin-dependent induction of Cyp1a1 gene transcription. Mol Cell Biol. 1992 May;12(5):2115–2123. doi: 10.1128/mcb.12.5.2115-2123.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Whitelaw M., Pongratz I., Wilhelmsson A., Gustafsson J. A., Poellinger L. Ligand-dependent recruitment of the Arnt coregulator determines DNA recognition by the dioxin receptor. Mol Cell Biol. 1993 Apr;13(4):2504–2514. doi: 10.1128/mcb.13.4.2504-2514.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Whitlock J. P., Jr Mechanistic aspects of dioxin action. Chem Res Toxicol. 1993 Nov-Dec;6(6):754–763. doi: 10.1021/tx00036a003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES